![]() |
|
|
Department of Psychiatry and Behavioral Sciences, Emory University
School of Medicine, Atlanta, Georgia 30322
The glucocorticoid receptor (GR) is a ligand-regulated transcription
factor that in its unactivated form resides primarily in the cytoplasm.
After being bound by steroid, the GR undergoes a conformational change
and translocates to the nucleus, where it influences gene
transcription. Because the GR mediates negative feedback exerted by
circulating glucocorticoid hormones on the hypothalamic-pituitary-adrenal (HPA) axis, it has been hypothesized that abnormalities in GR expression and/or function may underlie the
HPA axis hyperactivity described in patients with major depression. In
further support of this hypothesis, animal studies have shown that long
term in vivo treatment with antidepressants enhances glucocorticoid feedback inhibition, possibly through a direct effect on
the GR. To examine this latter possibility, we evaluated translocation
of the GR from the cytoplasm to the nucleus after 24-hr in
vitro treatment of L929 cells (mouse fibroblasts) with the
tricyclic antidepressant desipramine (0.1-10 µM) in the
presence or absence of the synthetic steroid dexamethasone. In
addition, GR-mediated gene transcription was measured with the use of
L929 cells stably transfected with the mouse mammary tumor
virus-chloramphenicol acetyltransferase reporter gene. Desipramine was
found to (i) induce GR translocation from the cytoplasm to the nucleus
in the absence of steroids (with no effect alone on GR-mediated gene transcription) and (ii) potentiate dexamethasone-induced GR
translocation and dexamethasone-induced GR-mediated gene transcription.
Treatment with desipramine for 24-96 hr had no effect on the
expression of GR protein as measured by cytosolic radioligand receptor
binding. We suggest that one important aspect of the effects of
antidepressants in vivo may be to facilitate GR-mediated
feedback inhibition on the HPA axis, by facilitating GR translocation
and function, and thereby reverse glucocorticoid hypersecretion in
depression.
This article has been cited by other articles:
![]() |
C. M. Pariante The glucocorticoid receptor: part of the solution or part of the problem? J Psychopharmacol, July 1, 2006; 20(4 Suppl): 79 - 84. [Abstract] [PDF] |
||||
![]() |
C. Maddock, A. Baita, M. G. Orru, R. Sitzia, A. Costa, E. Muntoni, M. G. Farci, B. Carpiniello, and C. M. Pariante Psychopharmacological Treatment of Depression, Anxiety, Irritability and Insomnia in Patients Receiving Interferon-{alpha}: a Prospective Case Series and a Discussion of Biological Mechanisms J Psychopharmacol, March 1, 2004; 18(1): 41 - 46. [Abstract] [PDF] |
||||
![]() |
C. L. Raison and A. H. Miller When Not Enough Is Too Much: The Role of Insufficient Glucocorticoid Signaling in the Pathophysiology of Stress-Related Disorders Am J Psychiatry, September 1, 2003; 160(9): 1554 - 1565. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lyu, J.-A Kim, S. K. Chung, K.-S. Kim, and C.-K. Joo Alteration of Cadherin in Dexamethasone-Induced Cataract Organ-Cultured Rat Lens Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2034 - 2040. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. McQUADE and A. H. Y. YOUNG Future therapeutic targets in mood disorders: the glucocorticoid receptor The British Journal of Psychiatry, November 1, 2000; 177(5): 390 - 395. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Pariante, B. D. Pearce, T. L. Pisell, C. I. Sanchez, C. Po, C. Su, and A. H. Miller The Proinflammatory Cytokine, Interleukin-1{alpha}, Reduces Glucocorticoid Receptor Translocation and Function Endocrinology, September 1, 1999; 140(9): 4359 - 4366. [Abstract] [Full Text] |
||||
![]() |
K. Okamoto, H. Tanaka, H. Ogawa, Y. Makino, H. Eguchi, S.-i. Hayashi, N. Yoshikawa, L. Poellinger, K. Umesono, and I. Makino Redox-dependent Regulation of Nuclear Import of the Glucocorticoid Receptor J. Biol. Chem., April 9, 1999; 274(15): 10363 - 10371. [Abstract] [Full Text] [PDF] |
||||